Advertisement

Topics

Sage Therapeutics and Shionogi & Co., Ltd., Enter Strategic Collaboration to Develop and Commercialize SAGE-217 for MDD and Other Indications in Japan, Taiwan and South Korea

20:01 EDT 13 Jun 2018 | Businesswire

This article has expired, however you can still download the PDF.
Preview:
Collaboration intended to accelerate development of SAGE-217 in key Asian markets and supports Sage’s mission to bring transformational medicines to patients around the world Collaboration supports Shionogi’s vision...

Other Sources for this Article

Sage Therapeutics:
Investors:
Paul Cox, 617-299-8377
paul.cox@sagerx.com
or
Media:
Maureen L. Suda, 585-355-1134
maureen.suda@sagerx.com
or
Shionogi & Co., Ltd:
Corporate Communications Department, +81-6-6209-7885

NEXT ARTICLE

More From BioPortfolio on "Sage Therapeutics and Shionogi & Co., Ltd., Enter Strategic Collaboration to Develop and Commercialize SAGE-217 for MDD and Other Indications in Japan, Taiwan and South Korea"

Advertisement
Quick Search
Advertisement
Advertisement

 

Relevant Topics

Mergers & Acquisitions
Commercial and market reports on mergers and acquisitions in the biotechnology, pharmaceutical, medical device and life-science industries. Mergers and acquisitions (abbreviated M&A;) is an aspect of corporate strategy, corporate finance and manageme...

Biotechnology Business
Alliances Astrazeneca Bioethics Boehringer Clinical Research Organization Collaborations GSK Johnson & Johnson Lilly Merck Mergers and Acquisitions Nexium Novartis Pfizer Roche Sanofi ...